{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.210","meta":{"versionId":"7","lastUpdated":"2023-07-07T01:01:08.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"American Society of Clinical Oncology Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2023-07-07"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-07-07"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.210","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.1444.3.210"}],"version":"20230707","name":"MultigenePanel","title":"Multigene Panel","status":"active","date":"2023-07-07T01:01:08-04:00","publisher":"American Society of Clinical Oncology Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of multigene panel.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for multigene panel that includes testing for BRCA1 and BRCA2.),(Exclusion Criteria: No exclusions.)","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","concept":[{"code":"81432","display":"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53"},{"code":"81433","display":"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11"}]}]},"expansion":{"identifier":"urn:uuid:09ff4464-a7a4-4c9b-be8f-73e5576d3e52","timestamp":"2023-12-11T01:19:36-05:00","total":2,"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"81432","display":"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"81433","display":"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11"}]}}